Literature DB >> 3598235

Development of beta-lactam-resistant Enterobacter cloacae in mice.

B Marchou, M Michea-Hamzehpour, C Lucain, J C Pechère.   

Abstract

We compared the ability of four newer beta-lactam compounds to produce resistance in an experimental model of Enterobacter cloacae infection. Mice infected intraperitoneally developed resistance depending on antibiotic treatment and the dose given. Percentages of mice in which resistance was observed were as follows: 100% after ceftriaxone (50 mg/kg, two doses); 87% after ceftriaxone (50 mg/kg, one dose); 35% after ceftriaxone (500 mg/kg, one dose); and 21% after carumonam (25 mg/kg, two doses). No resistance occurred after therapy with either BMY 28142 (25 mg/kg, two doses) or Sch 34343 (50 mg/kg, two doses). Heterogeneous resistance to beta-lactams among the cells within a given Enterobacter population accounted for these differences. The minimal concentration inhibiting the growth of the preexisting resistant variants, together with the antibiotic concentrations obtained in the peritoneal fluid, were associated with further emergence of resistance in the mouse treated with this antibiotic.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598235     DOI: 10.1093/infdis/156.2.369

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  Resistance to third generation cephalosporins: the current situation.

Authors:  J C Pechère
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

2.  Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Authors:  J C Fung-Tomc; E Gradelski; E Huczko; T J Dougherty; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Protective effect of amdinocillin against emergence of resistance to ceftazidime in Enterobacter cloacae.

Authors:  E Yourassowsky; M P van der Linden; M J Lismont; F Crokaert; Y Glupczynski
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

4.  Emergence of resistance during beta-lactam therapy of gram-negative infections. Bacterial mechanisms and medical responses.

Authors:  J C Pechère
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Transient in vivo selection of a constitutively cephalosporin resistant Enterobacter cloacae causing ventriculitis.

Authors:  A Joffe; A Kabani; K Ramotar; W Krulicki; G Cadrain; T Jadavji
Journal:  Can J Infect Dis       Date:  1995-01

Review 6.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.

Authors:  J Fung-Tomc; E Huczko; M Pearce; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 9.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

10.  Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.

Authors:  M Michéa-Hamzehpour; R Auckenthaler; P Regamey; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.